Anti-neoplastic viral agents

Details Anti-neoplastic viral agents Anti-neoplastic viral agents

2006-07-18

2006-07-18

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S199100, C424S233100, C514S04400A, C435S235100, C435S320100

Reexamination Certificate

active

07078028

ABSTRACT:
A viral DNA construct, and virus encoded thereby, is provided having one or more tumour specific transcription factor binding sites in place of one or more wild type transcription factor binding sites operatively positioned in the promoter region which controls expression of early genes responsible for viral nucleic acid replication.Preferred constructs place the tumour specific transcription factor binding sites in operative relation to DNA polymerase, DNA terminal protein and/or DNA binding protein.Compositions and constructs contained therein are provided, particularly for use in therapy. Methods of treating patients for neoplasms are also provided.

REFERENCES:
patent: 5155020 (1992-10-01), Paoletti
patent: 6544507 (2003-04-01), Iggo et al.
patent: 94/18992 (1994-02-01), None
patent: 96/34969 (1996-05-01), None
patent: 96/17053 (1996-06-01), None
patent: 96/36365 (1996-11-01), None
patent: 98/13508 (1997-09-01), None
patent: 98/35028 (1998-01-01), None
patent: 98/39464 (1998-03-01), None
patent: 98/41631 (1998-03-01), None
patent: WO 98/39464 (1998-09-01), None
patent: 99/25860 (1999-05-01), None
Korinek et al Science 275(Mar. 21, 1997): 1784-1787.
Ketner et al PNAS USA 91:6186-6190, 1994.
Monaco et al TIBTECH 12:280-286, 1994. (Abstract only).
Haviv et al (Current Gene Therapy 3:357-385, 2003).
Kanerva et al (Int. J. Cancer 110:475-480, 2004).
Saukkonen et al (Expert Opin. Biol. Ther. 4(4)683-696, 2004).
“Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35”, Christopher F. Basler et al. Gene. 170 (1996) pp. 246-254.
“Adenovirus early region 3 promoter regulation by E1A/£1B is independent of alterations in DNA binding and gene activation of CREB/ATF and AP1”, Masayo Kornuc et al, Journal of Virology, May 1990, pp. 2004-2013.
“Activation of the transcription factor Glil and the sonic hedgehog signalling pathway in skin tumours”, N. Dahmane et al, Nature, vol. 389, No. 389, Oct. 23, 1997, pp. 876-881.
“Expression of the RAG-2 gene in murine central nervous system tumor cell lines”, Tomokazu Aoki et al, Biochemical and Biophysical Research Communications, vol. 181, No. 1, Nov. 27, 1991, pp. 151-158.
“Targeting gene expression to hypoxic tumor cells”, Gabi U Dachs et al, Nature Medicine, vol. 3, No. 5, May 1997, pp. 515-520.
“The human telomerase catalytic subunit h TERT: organization of the gene and characterization of the promoter”, Y-Sheng Cong et al, Human Molecular Genetics, vol. 8, No. 1, 1999, pp. 137-142.
“Mutational Analysis of the APC/β-Catenin/Tcf pathway in colorectal cancer”, Andrew B. Sparks et al, Cancer research 58, Mar. 15, 1998, pp. 1130-1134.

Affiliated with

Also associated with

Rating

Anti-neoplastic viral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-neoplastic viral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-neoplastic viral agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3582661